Escolar Documentos
Profissional Documentos
Cultura Documentos
INTRODUCTION
1
INTRODUCTION:
2
MEANING OF INVENTORY MANAGEMENT:
Objectives:
3
In the contest of inventory management the firm is faced with the problem of
meeting to conflicting needs.
1 To meet the demand for the product by efficiently organizing the production
the production and sales operations.
2 Control investment in inventories and keep it at an optimum level.
3 To minimize investments in inventory.
4 To ensure against delays in deliveries.
5 To utilize the advantage of price fluctuations.
6 To take advantage of quality discount control.
4
OBJECTIVES OF THE STUDY
• To know the efficiency of the firm in utilizing its Current Assets in general
5
SCOPE OF THE STUDY
The scope of the study is limited to collect from last five years data of the
company and using of Ratios techniques of liquidity ratio, profitability ratios.
6
NEED FOR THE STUDY
Besides studying financial position one can study the entire organization as
financial analysis covers every aspect. This would be the primary reason that evoked
in the interest and need for the study.
7
METHODOLOGY
PRIMARY DATA:
Primary data means first hand information is collected by researcher
Primary data has been collected by interviewing various people in production
department as well as administrative people who will generally give the details
of inventory process and also know the existing software in the company. The
primary data has been collected from the personal observation and personal
interviews with the officials of the firm.
SECONDARY DATA:
Secondry data means already existing data. Which was collected by some one
else .The primary data was supplemented by the secondary data collected from
published annual general reports of the organization and some important presented in
the study with respect to HETERO DRUGS LTD., is taken from material data and
text book which has been matched with the record obtained from the company in
order to may a strategic view.
Internal records and files of HETERO DRUGS LTD.., including
information reports published material on transaction such as the Inventory
statements. Stock data registers have been analyzed interpreted.
8
LIMITATIONS
• Due to the limited time available the authenticity of conclusions drawn based
on the observations made cannot be ensured.
• The figures and facts claimed in the annual reports and other forms are
assumed true.
9
CHAPTER FRAMEWORK
Chapter-I First chapter deals with Introduction, Need, Scope, Limitation, Objectives,
of the study.
Chapter-III Third chapter covers the Company profile- Hetero Drugs ltd, Hetero
groups ,vision and mission values,R&D over review,operating
.
procedures,careers,offices,branch offices.
10
Chapter-VI Sixth chapter deals with Findings & Suggestions
CAPTER-II
INDUSTRY PROFILE
11
INDUSTRY PROFILE
12
The pharmaceutical industry is said to be the second fastest growing industry after
software industry. Pharmaceutical industry is perhaps the most challenging one on the
Indian industrial scene today. The total pharmaceutical market for the year 2002 is of
22000 crores. Pharma companies have out performed by substantial margin the 58
industries index covered by CMIE in terms of growth in sales profit after tax and asset
creation. Very intensive competition with about 16000 companies large, big, medium and
small fighting for their own place under the sun in an Rs.8500 crore (including bulk drugs
as per 1995 estimates). The competition is at its fiercest currently.
Increasing dominance of trade associations and their constant demand for increase
in trade margins. In the pharmacy industry firms have to come up with new drugs and
newer ways of combating existing as well as newly identified diseases. This makes the
industry highly R & D sales ratio [a standard measure of the technology intensity of an
industry world wide 5.5% for the electronics industry, 8% for computers and 16% for
pharmaceuticals.
The path of a drug evolution from molecular synthesis to fine approval by the FDA is
an expensive affair costing a few hundred million dollars for a single drug. The
13
possibility of the molecule or drug getting rejected because of side effects, or unacceptable
toxicity, exists at recovery stage of evolution. This implies a high degree of risk in Pharma
basic research. However, margins a potential drug command (especially under the patent
protection zone) makes basic research a high degree of risk and high gain game. Block
buster patented drugs are known to have brought in revenue of more than $ 1 billion a year
enabling the others not son successful products with in the company a piggy back side. In
short, it is a rat race, where a “better mouse-trap” just will not do. One needs much more
than that. And as in any jungle concrete or real only the fittest survive.
PHARMACEUTICAL INDUSTRY
From ancient times, two systems of medicine will in vague in India firstly, there
was Ayurvedic medicine, which dates back to the vedic period. Ayurvedic medicine
depends largely on the combination of various herbs, minerals and metals like gold, copper
etc. Secondly, there was the Arabian system of medicine. An innumerable invasion has
brought the Arabian system into India. In contrast to, two others systems of medicine,
namely Allopathic and Homeopathy, were in vague in the western part of the
world.Despite of being very advanced indigenous systems of medicine, Ayurvedic
medicine has not really become popular enough, probably because of very long British
Rule and the consequent development of an educational system including medical
educational based on a typical British model. As Allopathic or modern medicine started
taking roots in India, all the research and development activities the world over filled its
growth in India as well. Conversely, there was hardly any research and development
activity in the area of ayurvedic medicine. Though the government has been making some
efforts to promote ayurvedic medicine, its development seems to be a long way off.
It is still popular in rural areas, may be because modern medicine cannot reach
there. In urban areas it has yet to gain importance in so far as the prescription drug market
is concerned.
The indication of allopathic doctors towards prescribing an ayurvedic medicine is
14
very low indeed. Of late, however, the attitude of customers towards ayurvedic medicine
seems to be increasingly favorable. Some of the pharmaceutical companies are planning to
diversify into ayurvedic drugs mainly to improve their profitability ayurvedic drugs re
exempted from price control.
The exact date on which the allopathic systems of medicine make its entry into the country
is not available but it is generally estimated that it happened some time during the early
part of the 19th century. The Britishers for there personal use imported the medicines when
they come to do business. This was the beginning of the pharmaceutical industry in India.
Later, when they ultimately took over the country, the imports became a regular feature.
These pharmaceutical products, which were introduced in India to provide relief to
britishers, soon gained popularity among the people in urban areas. For the first few
decades after their introduction, pharmaceutical products were being imported into the
country, mostly from Germany and the United Kingdom.
Indigenous production of these medicines, however, was started in 1901 with the
establishment of the Bengal chemical and pharmaceutical works, due to the pioneering
efforts of Acharya P.C.Roy. the world of medical treatment was witnessing some
significant, developments, like Louis Pasteur’s discovery of pathogenic bacteria as the
cause of infectious diseases while the Indian Pharmaceutical industry was in its early
stages.
Scientists in India undertook research in tropical diseases like malaria, typhoid and
cholera. Between 19904 and 1907 four research institutes, namely The Haffkine Institute
and Pasteur Institute were established. Yet another significant development of this period
was the use of chemicals for treating various diseases. Some very important drugs like
aspirin and barbiturates were made available during this period.
15
The First World War gave a real stimulus to domestic production of pharmaceutical. There
was a step rise in demand and a drastic cut in imports. Consequently, the production of
quinine salts registered a substantial increase for the first time. Production of caffeine from
tea waste and manufacture of surgical dressings were also taken up during this period.
However with the resumption of imports after the war, the industry was back to square
one. It received a setback, s it was unable to compete with imported products.
The Bengal chemical and pharmaceutical works started production of tetanus antitoxin, a
basic drug in 1930. Indigenous production in 1939 was sufficient to meet only about 13
percent of medical requirements. Thus a large part of domestic demand for drugs was still
met by imports. The second world was another landmark in the history of the Indian
pharmaceutical industry it provided a propitious atmosphere for further expansion of
production.
By 1941, the industry took up the manufacture of new drugs like iodochlorohydroxy
quinoline as well as a number of alkaloids like ephedrine and codeine. Besides, the
industry made a beginning in the production of chemotherapeutic drugs like arsenicals,
anti-leporsy drugs and colloidal preparations of calcium, silver, manganese and iodine.
The production of glandular products like liver extracts was also undertaken. The
production of several formulations based on imported bulk drugs also showed a significant
expansion during the period.
16
industry. The estimated value of production of pharmaceuticals in 1947 and Rs.10 crores.
POST-INDEPENDENCE ERA
Immediately after independence, the government addressed itself to the task of achieving a
high rate of economic progress with special emphasis on speedy industrialization. When
the government of independent India embarked on planned economic expansion about four
decades ago, the development of the Indian pharmaceutical industry was not
commensurate with the size of the country and the growing needs of its population. Since,
then the progress of the pharmaceutical industry in the country has been substantial and
many sided can best be described as dramatic.
DRAMATIC PROGRESS
From a mere Rs.10 crore (production value) in 1947 to a whopping Rs.14, 160 crores in
2000 the pharmaceutical industry in India, has come a long way. Today India
manufactures over 400 bulk drugs and around 60000 formulations. The numbers of
pharmaceutical units too have increased from classification of the developing countries
according to the “state of the arts” in the pharmaceutical sector, India is ranked among the
top. Exports of bulk drugs and formulations too are showing a remarkable increase from a
total import –based technology. The Indian pharmaceutical industry has certainly 1970-71
the value of exports was Rs.10 crores. Pharmaceutical exports from formulations have
crosses the Rs.1200 crore mark in 1991-92, thus achieving a net exporter status in the
drugs and pharmaceutical industry. The dramatic progress of drug industry at a glance is
presented in the given table.
17
DRUG INDUSTRY: GROWTH INDICATORS
1947-48 1991-92
(Rupees in crores) (Rupees in crores)
Capital Investment 24(1952-53) 950
Production 10 4200
Formulations 18(1956-66) 790
Bulk Drugs
Imports 100 1000
Exports 1.27(1963-64) 1281
R & D Expenditure 6(1972-73) 70
INDUSTRY STRUCTURE
The present day Indian pharmaceutical industry has three main sectors:
The public sector
The Indian private sector ( including the organized sector) and
The foreign sector:
It is estimated that there are presently 16000 firms engaged in the production of drugs and
pharmaceuticals. About 300 units out of these are on the list of the Directorate
General of Technical Development.
PRODUCTIONBULK DRUGS
18
Bulk drugs are medically effective chemicals. They are derived from 4 type s of
intermediate (raw materials), namely prescription and these are called ethical products.
However, same formulation such as pain balms, health tonics etc can also be purchased by
users directly. These are called over the counter (OTC) products. Formulations can be
categorized as per the route of ministration t patients, viz. Oral i.e., tablets, syrups,
capsules, powders internally. Topical i.e., Ointments, creams, liquids, aerosols that are
applied on the skin Potentials i.e., sterile solutions injected in an extra venous or
intramuscularly fashion. Others such as eye drops, surgical dressing etc. Production of
formulations was valued at Rs.3840 crores in 1990-91. import of formulations is
negligible (Rs. 60 crores in 1990-91) and consists of specialized drug such as anti-cancer
drugs. The estimated value of formulation is around Rs.200 crores in 1991-92. the details
regarding the progress of pharmaceutical production in India are presented below.
EXPORTS:
19
At the time of independence there were no exports of pharmaceuticals from India.
The total value of exports of pharmaceuticals was a mere by Rs.3 crores in 1965-66.
During the last seven years, the Indian pharmaceutical industry has achieved commendable
progress on the export front. The industry total exports were valued at Rs.1281 crores in
1991-92. The progress of the industry in terms of exports can be seen in the tab
20
CHAPTER-III
ORGANISATION PROFILE
COMPANY PROFILE
HETERO DRUGS LTD
21
Established in the year 1993, with the motto to be the best in the API
manufacture, Hetero today embodies the vision of a top-notch player in developing
and commercializing products catering to a variety of therapeutic categories,
integrating into a leading finished dosage manufacturer.
True to the statement, “WHERE THE FUTURE STARTED
YESTERDAY”, with a foresight on the current trends in the pharmaceutical market,
HETERO has grown from strength to strength, combining its research strengths,
manufacturing capabilities, Human Resources and well established quality
management system. With full-fledged marketing capabilities the company has been
able to market its products in over 80 countries in Asia, Middle – east, Eastern,
Europe and Latin America.
With its compliance to the most stringent regulatory requirements, Hetero
has today gained foothold to market. Several of its APIs in the United States, Canada
and Europe. With all six manufacturing facilities being supported by excellent
infrastructure and compliance to the GMP requirements, Hetero has crossed
numerous milestones in a comparatively small period since its inception
HETERO GROUPS
22
FOUNDER & MILESTONES
• The spirit and brain behind the success story of Hetero is its founder
Dr.B.Parthasarathi Reddy, a scientist who started the company drawing
immense strength from the vast and rich experience he gained during his
earlier.
• Stint at the laboratory where he was instrumental in developing and
commercializing processes for several APIs.
• The company was started by him with a vision to be recognized as an
aggressive company that combines its strength of R&D and manufacturing
with definite advantages in terms of cost and chemistry with a strong
emphasis on quality of the products.
• The untiring efforts of the Chairman saw HETERO develop processes for
several products at relatively low cost, thus making it possible for several life
saving drugs to be available tat affordable prices, meeting all the regulatory
and quality norms.
• With the organization having reached a point where it is identified among the
widely recognized companies, the Chairman is now focusing on giving new
dimensions to the company in terms of exploring possibilities of further
growth, exploring new horizons in the field of pharmaceutical development
and evolving strategies to take the company to greater heights
• All the members of HETERO Family draw inspiration and motivation from
the Chairman in working towards achieving the organizational goal.
23
• Hetero visualizes itself as an aggressive player in the global pharmaceutical
scenario, supplying generics developed, combining intellectual property,
research strengths and strong human resource inputs.
• The company values the concepts of having social responsibilities ion the
course of its assent to greater heights. It strongly believes in focusing on
customer requirements and delivering the products at the right pace.
• Hetero considers its human resources as the core of all its capabilities and
believes in tapping and honing the talents of its members to reach the zenith of
success.
• It believes in continuous evaluation and improvement in all the factors that
contribute in transforming the organization into a global force to reckon with.
• Hetero takes due cognizance to the fact that the processes that it develops
should be all Eco- friendly and should not result in any consequence that
harms the ecological harmony.
MISSION
HETERO STRENGTH
24
• Strong emphasis on Research and Development.
• Ability to develop processes for a large range of therapeutic categories.
• Ability to orient and adapt to the changing facets of industry, particularly in
terms of regulations, intellectual property and manufacturing capabilities.
• Cohesive team of skilled professionals in all wings related to research,
manufacture and marketing.
• Strong customer base and market presence.
• A strong commitment towards the society to provide timely support by
providing life saving drugs at relatively low costs, short span of time
CAPABILITIES:
25
• Differential Scanning Calorimeters
• P-XRD
• NMR
• GCMS
• LCMSM
QUALITY SYSTEMS
All the activities at HETERO right from receipt of raw materials to dispatch of the
finished product are carried out in accordance to a well-oiled quality management
system. The importance of having a strong quality based system has been recognized
by organization due to which every individual in each department understands
his/her responsibilities and carries out them with utmost care avoiding any confusion,
thus delivering the best results.
In addition, talking about quality of the product itself, the company has
evolved the systems to implement GMP’s in the manufacture of the product to
protect the safety, quality and integrity. The approval of Hetero’s API Facility by
USFDA and Finished Dosage Facility by WHO bear a testimony to this fact.
26
R & D OVERVIEW
27
STANDARD OPERATING PROCEDURES
Procedure:
28
• After de-dusting bring the decoding list and deface the original name of the
material on each container or bags and write in-house code of the material.
Before defacing check the label on each container for vendor batch number
and weight.
• Transfer the material to quarantine area. Enter the details into the inward
registar. Allot the in-house batch numbers to the consignment.
• If the number of containers shall be less than 25 then the under test label shall
be pasted on all containers. If it is more than 25 then the under test labels shall
be pasted along four corners of the consignment
Sampling and Testing:
• The warehouse personnel shall then raise a” raw material alert to Quality
Control” for sampling and analysis of the consignment
• The Quality Control personnel shall paste the sampled labels on the containers
from which the samples were taken.
• The Quality Control personnel shall paste Approved/Rejected labels on the
yellow of the under test labels of the consignment.
Storage and Handling:
• Raw Material shall be stored in such a manner that proper spacing between
different lots of the same material and also different material to avoid cross-
contamination between the materials.
• Inventory cards along with the raw material alert and pre-inspection report
shall also be placed along with the status boards.
• Special storage conditions are essential for the raw material say low
temperature and low humidity
29
• On receipt of the raw material request from the production department the
warehouse personnel shall issue the requisite quantity of raw material to the
concerned production department.
• The warehouse personnel shall then enter the details of issue of the material in
the inventory card.
• While issuing the material to the production department, the warehouse
personnel shall follow the “First In First Out system”.
Re-testing of Raw Material:
• Raw materials being stored for longer periods of time shall be re-tested from
time to time i.e., within 5 days of re-test date.
30
After receiving the goods transfer note from the production department it is the
responsibility of the warehouse personnel
• All the dispensing equipment like scoop, measuring jars, funnels and buckets
barrels pumps etc should be cleaned after their use.
• After completion of dispensing operations transfer the dispensing equipments
to wash area and rinse the dispensing equipment with water after wearing
goggles, nose masks and hand gloves.
• Cover the hosepipe ends, scoops, funnels, buckets etc and pump end with
clean polythene bag/rexine cover and keep the dispensing equipment in their
dedicated area.
Sanitation
31
• De-dust the entire area using nylon soft broom.
• Mop the floor with clean cloth if not satisfied repeat it again.
• Frequency-Everyday in the first shift
Sampling Room:
Dispensing Room:
• Clean the room before starting dispensing activity and after completion of
every dispensing operation.
• Use vacuum cleaner to suck all dust.
• Mop the floor with water and allow to dry if not satisfied repeat it again.
• Details shall be entered in the sampling and sanitation record.
• Frequency-Every after dispensing operation
Solids:
32
• After receiving raw material requesting check whether all details are entered
or not.
• Raw Material shall be taken into the dispensing room. Material shall be taken
using a clean scoop and tie the bags tightly after dispensing.
• A tag shall be assigned there remaining quantity of the material and the details
shall be entered in the inventory card.
• Drums shall be cleaned with a clean cloth and open the lid with drum opener.
• Measure the volume with guage rods/measure jars/buckets/by weighing.
• Transfer the required quantity of solvent by using PVC siphon pipe/barrel
pump and drums shall be closed tightly.
33
• All the hosepipes shall be colored as mentioned in the Annexure.
• Before starting of operation the hosepipe shall be cleared with 5 to 10 liters of
the same solvent and discard it.
• Upon completion of operation, when not in use, the ends of the pipe shall be
covered with rexine covers/polythene bags and store at the designated place
keeping both the ends of the pipe facing down.
• Hosepipe shall be checked monthly once and if any damages the pipe shall be
discarded and new pipe shall be used.
• Enter the details of checking and replacement of pipe in the record.
• Pipes shall be replaced with new one after completion of 3 years of usage.
CAREERS
34
• HETERO considers its Human Resources as its core strength. The company
believes in the fact that its present position as an aggressive player can be
attributed to the efforts on part of all its employees working in different
departments in realizing its goal of being a Top Notch Company.
• The Company offers the best of the opportunities to work, where the potential
and capabilities of personnel are tapped to the maximum advantage of both
the organization and the personnel. The latent talents are honed to meet the
challenges faced by the organization and achieve the best.
OFFICES
35
Corporate Office
HETERO DRUGS LIMITED
“Hetero House”
H.no.8-3-166/7/1,Erragadda,
Hyderabad-500018,
(A.P)INDIA
Tel: +91-40-23704923/24/25
Fax: +91 – 40 – 23704926, 23714250
E- mail:
Contact@heterodrugs com
BRANCH OFFICES
36
CHAPTER-IV
37
Inventory management is the active control program, which allows the
management, sales, purchases and payments.
Purpose of Inventory
The only inventory that is required is that which is actually being processed
in a manufacturing environment or being delivered to a customer in a distribution
38
environment. Leading companies in all industries recognize that inventory usually
indicates a potential area of improvement; it is a symptom rather than an asset.
Traditional approaches to inventory management include six reasons for
carrying inventory. While each of the reasons seems valid, especially in the short
term, each reason also represents a failure to operate in the most efficient or effective
manner.
Those are as follows:
• Price protection: Buying large quantities at one time has been a traditional
hedge against price increases. You can negotiate pricing and long-term contracts
with key suppliers, but you should request multiple deliveries. As your suppliers
implement lean practices, they will strongly prefer to ship smaller quantities at
frequent intervals, rather than asking you to take delivery of the entire purchased
amount at once. Pricing agreements should also include the possibility of cost
reductions, automatically passing on the supplier’s cost reductions.
• Quantity discounts: Some suppliers offer discounts for buying large quantities.
Quantity discounts work just like price protection. Quantity discounts are being
replaced today by key supplier agreements, in which you agree to purchase your
entire year’s usage of various product families from one supplier in exchange for
highly favorable pricing, superb service, impeccable quality, and rapid response and
delivery. This reflects a culture of partnering with key suppliers rather than treating
them as adversaries.
Types of Inventory
TYPES OF INVENTORY
IN-PROCESS
- REJECTED -REJECTED - REJECTED
- APPROVED -APPROVED - APPROVED
INTERMEDIARIES
-REJECTED
-APPROVED
SEMI-FINISHED GOODS
-REJECTED
Inventory can be falls under three basic categories:
-APPROVED
Raw materials
Work –in- progress.
Finished Goods
41
Raw Materials:
These are the Inputs to produce the products. It includes direct material used
in the manufacture of a product and it also includes the components, fuel etc. used in
the manufacture.
These raw materials can be again divided in to two categories. They are: Approved
raw material: Raw materials can be checked by the Quality Control people by using
certain Quality Control Methods. If they are approved after applying those methods
label can be pasted by the quality control people called ‘Approved Label’. It is in
green colour.
42
• Intermediaries: The material which is in middle of the production process for
final product is called Intermediaries.
43
DHARNI 0 700 0 0 0 0 0 0 0 250 0 0
0
V SALT 0 4000 0 0 0 300 0 3000 300 0 3000
0 0 300
KAKI- 100 2000 490 200 3040 252 1050 0 0 1520
320 0 0 0 0 580
2020 202 2020 3995 0 0 249 4540
HYFLOW 149 0 202 404 204 7
8 0 0 3 249 254
7 2
7000
6000
5000 DHARANI
4000 VSALT
3000 KAKI-320
2000 HYFLOW
1000
0
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
From the above graph we can understood that how different raw materials are In
warded throughout the year.Hyflow,Kaki-320 & V salt raw materials are Inwarded
more & Dharani material is inwarded less in the year 2008-2009.
RAW MATERIAL INWARD FOR THE YEAR APR 2007-MAR 2008 (In
44
Units)
ITEMS APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
200 200
DHARANI 0 3000 0 0 4000 0 0 0 0 0 0 1000
200 1300 700 100 100 200 200 100
V SALT 0 0 0 0 2000 0 0 2000 0 0 0 2000
300 100 100 100 200
KAKI-320 0 2000 0 0 0 0 0 1000 0 0 0 1575
499 299 499 227
HYFLOW 4 1997 6 4 0 0 998 2247 0 499 998 2270
14000
12000
10000 DHARANI
8000 VSALT
6000 KAKI-320
4000 HYFLOW
2000
0
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
From the above graph we can understood how different raw materials
are Inwarded throughout the year.Hyflow & V salt raw materials are Inwarded
throughout the year.Dharani & Kaki-320 raw materials are inwarded less in the year
2007-2008.
45
RAW MATERIAL INWARD FOR THE YEAR APR 2006-MAR 2007 (In
Units)
ITEMS APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
DHARAN 300 1500 200
I 2000 1000 0 0 2000 3000 6000 2000 2000 0 0 7000
1700 400 500 1100 1200 1050 1400 500
V SALT 4000 0 0 0 0 0 7500 0 0 5000 0 9950
100 100 100
KAKI-320 0 1000 0 0 1000 0 1000 2000 1000 0 0 2120
299 199
HYFLOW 2996 4994 6 0 1997 5992 5992 3995 0 1997 7 3995
18000
16000
14000
12000 DHARANI
10000
V SALT
8000
KAKI-320
6000
4000 HYFLOW
2000
0
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
46
From the above graph we can understood how different raw materials
are Inwarded throughout the year.V salt & Dharani raw materials are Inwarded more
through out the year.Hyflow & Kaki-320 raw materials are inwarded less in the year
2006-2007
RAW MATERIAL INWARD FOR THE YEAR APR 2005-MAR 2006(In
Units)
ITEMS APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
200 600 200 2000
DHARANI 0 2000 0 0 4000 6000 0 0 0 0 0 0
145 250 305 1200 500
V SALT 0 5000 0 0 3000 0 0 0 5000 0 0 8000
100 100 100 100 100 100
KAKI-320 0 0 0 0 1000 1000 0 1000 0 0 0 1000
199 299 349 199 199 136
HYFLOW 7 2996 6 5 3495 0 7 3995 1997 7 2 3632
s
Note: ORGINAL NAMES USED FOR ABOVE DECODED MATERAILS
DHARANI : Sodium Bi Carbonate
V SALT : Vaccum Salt
HYFLOW : Hyflow Super Cell
KAKI – 320 : Acetavated Carbon 320
47
25000
20000
DHARANI
15000
VSALT
10000 KAKI-320
HYFLOW
5000
0
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
From the above graph we can understood how different raw materials
are Inwarded throughout the year.V salt raw material was Inwarded continuously
through out the year but Dharani raw material was inwarded only upto the month
December.Hyflow & Kaki-320 raw materials are inwarded less in the year 2005-
2006.
RAW MATERIAL INWARD FOR THE YEAR APR 2004-MAR 2005 (In
Units)
ITEMS APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
DHARAN 1800 1570 500 300 300 220
I 0 0 0 0 0 0 0 2000 0 0 0 3500
1000 250
V SALT 0 5000 0 0 0 0 0 0 0 0 0 0
100 100 100 100 100
KAKI-320 1000 0 0 0 1000 0 0 0 0 0 0 1000
199 199 299 149 199 249
HYFLOW 2497 0 7 7 1997 6 0 0 8 7 7 0
48
V SALT : Vaccum Salt
HYFLOW : Hyflow Super Cell
KAKI – 320 : Acetavated Carbon 320
20000
18000
16000
14000 DHARANI
12000
VSALT
10000
8000 KAKI-320
6000 HYFLOW
4000
2000
0
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
From the above graph we can understood how different raw materials
are Inwarded throughout the year.Dharani, Hyflow & Kaki-320 raw materials are
inwarded continuously through out the year but V salt was Inwarded less in the year
2004-2005.
PURCHASING PLAN
The purchasing plan details:
49
To maintain an in-stock position of wanted items and to dispose of
unwanted items, it is necessary to establish adequate controls over inventory on order
and inventory in stock. There are several proven methods for inventory control.
They are listed below, from simplest to most complex.
•Visual control enables the manager to examine the inventory visually to
determine if additional inventory is required. In very small businesses
where this method is used, records may not be needed at all or only for
slow moving or expensive items.
•Click sheet control enables the manager to record the item as it is used on a
sheet of paper. Such information is then used for reorder purposes.
50
• Point-of-sale terminals relay information on each item used or sold. The
manager receives information printouts at regular intervals for review
and action.
• Off-line point-of-sale terminals relay information directly to the supplier's
computer who uses the information to ship additional items
automatically to the buyer/inventory manager.
1. The order quantity, that is, the size and frequency of orders; and
2. The reorder point that is, the minimum stock level at which additional
quantities are ordered.
52
• Increasing inventory turnover--but not sacrificing the service Level.
• Keeping stock low--but not sacrificing service or performance.
• Obtaining lower prices by making volume purchases--but not ending up with
slow-moving inventory and
• Having an adequate inventory on hand--but not getting caught with obsolete
items.
The degree of success in addressing these concerns is easier to gauge
for some than for others. For example, computing the inventory turnover ratio is a
simple measure of managerial performance. This value gives a rough guideline by
which managers can set goals and evaluate performance, but it must be realized that
the turnover rate varies with the function of inventory, the type of business and how
the ratio is calculated (whether on sales or cost of goods sold). Average inventory
turnover ratios for individual industries can be obtained from trade associations.
CHAPTER-V
53
DATA ANALYSIS AND INTERPRETATIONS
54
Time)
• Maximum Stock Level: It represents the upper limit beyond which the quality
of any item is not normally allowed to rise to ensure that unnecessary working
capital is not blocked in stock items. Maximum stock level represents the total
of safety stock level and economic order quantity. Maximum stock level can
be expressed in the formula given below:
ORDERING LEVEL
The annual consumption of an item and the time lag between ordering
and receiving can be collected from past records. Based on these facts and policies,
the ordering level and ordering quantity of Hetero Drugs Ltd. can be calculated, as
follows:
(OR)
The ordering level should be fixed so that when an indent is placed at the
ordering level, the stock reaches the minimum level when the replenishment is
received. The ordering level is calculated from the following factors:
55
3. The lead time
Q. Calculate Maximum level, Minimum level, Ordering level & Average level
Example of Material: D (-) Mandalic acid
Solution:
ORDERING LEVEL = Maximum usage x Maximum deliveryperiod
=420 x 8 = 3360 Kgs
56
= 9360-720
= 8640 Kgs
Q. Calculate Maximum level, Minimum level, Ordering level & Average level
Example of Material: Di isopropyl ether
57
MAXIMUM USAGE LEVEL = (Ordering level + Ordering quantity) –
(Minimum usage x Minimum delivery period)
= (5600 + 12000) – (350 x 6)
= 15500 Kgs
58
stock fall to a low level, rather than having wait for the next re-order date.
59
‘A’ Class Items ‘B’ Class Items ‘C’ Class Items
60
The technique tries to analyze the distribution of any characteristics by
stock values of importance in order to determine its priority. This technique can be
applied in all facets of organization. Many organizations are applying this technique
in materials management and spare parts management to identify the contribution
made by the materials/spares in the total inventory value. On the basis of stock value,
materials procurement strategy and consumption strategy is decided.
61
ABC ANALYSIS OF 30 STOCK MATERIAL FOR THE PERIOD 2004-05
CLASS A MATERIAL CLASS B MATERIAL CLASS C MATERIAL
Material
code Annual usage Material code Annual usage Material code Annual usage
Chanti 1004614 Aarthi 612500 AC-501 6136
Colin 861220 Ankita 572707 Bony mix 72406
7 Up 1939860 BPL 160500 Brisk 45056
DSP 671550 C.P.Flakes 248527 Buffer 120890
Honey 676522 C.S.Flakes 232339 Canon 28090
Cat-HH 141525 Cat-C 14994
Dharani 206895 Cat-H 116901
Maaza 383350 Champion 56848
Complan 62130
Dandi 6600
DCM 52080
Dimple 12500
Dranex 3400
Captain Cook 156000
Tata tea 2060
Kores 46400
Limca 10500
62
MATERIALS
CHANTI: FORMALDEHYDE
COLIN: 1 4 DIOXANE
7UP: 2-METHYL PIPERZINE
DSP: PYRIDINE
HONEY: BENZENE SULFONIC ACID
AARTHI: 3,3A,4,5,6,7,-2H-HEXA HYDRO INDOLE-2-CARBOXTLIC
ACID HYDROCHLORIDE
ANKITA:PHENYL ISOCYANATE
BPL: TITANIUM TETRA ISOPROPO
C.P.FLAKES: CAUSTIC POTASH FLAKES
C.S.FLAKES: CAUSTIC SODA FLAKES
CAT – HH: HYDROZEN HYDRIDE 100%
DHARANI:SODIUM BI CARBONATE
MAAZA: L-PROLINE
AC – 501: E.D.T.A
BONY MIX: TRIETHYL AMINE
BRISK: FORMIC ACID
BUFFER: DI SODIUM PHOSPHATE
CANON: CALCIUM CARBONATE
CAT – C: TETRA BUTYL AMMONIUM BROMIDE
CAT-H: HYDROZEN HYDRIDE
CHAMPION: L-ALANINE
COMPLAN: 2 CHLORO METHYL 3,5 DIMETHYL 4 METHOXY
PYRIDINE HCL
DANDI:SODIUM ACETATE (ANHYDROUS)
63
DCM: DI METHYL CARBONATE
DIMPLE: 2 MARCAPTO BENZIMIDAZOLE
DRANEX: TRITYL CHLORIDE
CAPTIAN COOK:P.T.S CHLORIDE
TATA TEA: MONO METHYL AMINE 40%
KORES: CUMENE HYDRO - PEROXIDE.
LIMCA: DIMETHYL FORMAMIDE
64
C Class item is 9.60%
65
Seeta: CITRIC ACID MONO HYDRATE
Jasmine: TRIBUTYL TIN CHLORIDE
Durban: L-VALINE
Reeta: BENZYOL CHLORIDE
Hazard:
Dabur: ACETONITRILE
Dhanraj: 1,2,BENZISOTHIAZOLINE-3ONE
Henko: 1 HYDROXY BENZO TRIAZOLE
Hema: SODIUM-2-ETHYLHEXANOATE
Nutrine: SODIUM METHOXIDE
Tata tea: MONO METHYL AMINE 40%
Dimple: 2 MARCAPTO BENZIMIDAZOLE
Maaza: L-PROLINE
Brisk: FORMIC ACID
Chanti: FORMALDEHYDE
SBH: SODIUM BORO HYDRIDE
Ankita: PHENYL ISOCYANATE
BPL: TRANS-4PHENYL-PROLINE
Thinner: P.T.S ACID
Sunil: PHOSPHORIC ACID 85%
Sagar: SULFOMIC ACID
Kaki-320: ACETAVATED CARBON 320
Dharani: SODIUM BI CARBONATE
Eno carbon: ENO CARBON
Champion: L-ALANINE
Kasthuri: VANADYL ACETYL ACETONA
66
Percentage of A Class item is 96.50%
B Class item is 2.60%
C Class item is 0.80%
67
ABC ANALYSIS OF 30 STOCK MATERIALS FOR THE PERIOD 2006-07
CLASS A MATERIALS CLASS B MATERIALS CLASS C MATERIALS
Material Annual Material Annual Annual
code usage code usage Material code usage
Cycle 11778400 C.P.Flakes 191611 7 Up 2925
Bony mix 1395558 Bacardi 269640 AC-501 5664
C.S.Flakes 2378040 Captian cook 126750 Amisha 10050
Ammonium
Ankitha 1049670 Castrol 724572 formate 15000
Arundhathi 838559 Cat-HH 267399 Anamika 15000
Colin 123420 BPL 5778
Dharani 402930 Bogi 900
Duran 200850 Brisk 28644
DCM 101122 Amruthanjan 93000
Cat-C 49504
Cat-H 66030
Chakobar 9025
Chanti LR 15015
Dabour 28500
Dandi 17292
Dimple 1250
68
NOTE: ORIGINAL NAMES USED FOR ABOVE DECODED MATERIALS
69
Chakobar: TRANS -4- HYDROXY -L- PROLINE(DEEC)
Chanti LR: FORMALDEHYDE
Dabur: METHYL(R)-(-)-3-HYDROXY BUTYRATE
Dandi: SODIUM ACETATE (ANHYDROUS)
Dimple: 2 MARCAPTO BENZIMIDAZOLE
70
C Class item is 1.80%
Bogi 2500
Patna 17800
Amisha 7000
Juhichawala 51220
Menthal 47505
Cat-H 18786
Henko 8100
71
NOTE: ORIGINAL NAMES USED FOR ABOVE DECODED MATERIALS
Chakobar: TRANS -4- HYDROXY -L- PROLINE(DEEC)
Frooty: TETRA HYDROFURAN
Picnic: 4-PHENYL BUTANE -1
Bonymix: TRIETHYL AMINE
Hazard: ACETONITRILE
Champion: L-ALANINE
Reeta: BENZYOL CHLORIDE
Arundati: TRI METHYL SILYL CHLORIDE
Kaki-320: ACETAVATED CARBON 320
Henna: CYCLO HEXANE
Chanti: FORMALDEHYDE
Manasa: D (-) MANDALIC ACID
Sesikala: HYDRO BROMIC ACID
RM – 162: METHANE SULPHONYL CHLORIDE
Konica: DIMETHYL SULPHOXIDE
Maaza: L-PROLINE
Saffola: N,N DICYCLO HEXYL CORBIDIMIDE
Brisk: FORMIC ACID
Mypol: N-METHYL PIPERZINE
Lalu: LIQUID BROMINE
Sunil: PHOSPHORIC ACID 85%
Thinner: P.T.S ACID
Tamrind: L+ TARTARIC ACID
Bogi: OXALIC ACID
Patna: SODIUM PERSULPHATE
72
Amisha: AMMONIUM CHLORIDE
Juhichawala: PHENYL CHLORO FORMATE
Menthal: SODIUM TUNGASTANATE
Cat-H: HYDROZEN HYDRIDE
Henko: 1 HYDROXY BENZO TRIAZOL
74
ABC ANALYSIS OF 30 STOCK MATERIALS FOR THE PERIOD 2008-09
Anamika 43,950
Anchor 4,600
Dhanraj 2,764
Limca 8,600
75
Sredevi: N2-(1-(S)-ETHOXYCABONY-3-PHENYPROPYL)-N6-
RIFLUOROACETYL -L-LYSINE BENZL ESTER
Manasa: D (-) MANDALIC ACID
ZDC: N,N CORBONYL DI IMDAZOLE(DEEC)
Picnic: 4-PHENYL BUTANE -1
Dabur: METHYL(R)-(-)-3-HYDROXY BUTYRATE
Richa: PTHALIMIDO AMLODIPINE
Maaza: L-PROLINE
Orpat: INDOLE-2-CARBOXYLIC ACID
Chachobar: YDROXY -L- PROLINE(DEEC)
Aarthi: 3,3A,4,5,6,7,-2H-HEXA HYDRO INDOLE-2-CARBOXTLIC ACID
HYDROCHLORIDE
Frooty: TETRA HYDROFURAN
Hazard: ACETONITRILE
Saffola: CYCLO HEXYL CORBIDIMIDE
Sunrise: CINCHONIDINE BASE HYDROUS
Sunil: PHOSPHORIC ACID 85%
Honey: BENZENE SULFONIC ACID
Kaki-320: ACETAVATED CARBON 320
Cat-S: 1,4 DIMETHYL AMINO PYRIDINE
Thiophene: THIOPHENE
Zing thing: HYDROZEN PEROXIDE
Eno Carbon: ENO CARBON
Anaconda: VITRIDE(SODIUM DIHYDROBIS (2-
METHOXYETHOXY)ALUMINTE TOLUNE
Seeta: TRIC ACID MONO HYDRATE
Champion: L-ALANINE
76
Dharani: SODIUM BI CARBONATE
7 Up: 2-METHYL PIPERZINE
Anamika: ORTHO FLURO NITRO BENZENE
Anchor: PROPINIC ANHYDRIDE
Dhanraj: 2,BENZISOTHIAZOLINE-3ONE
Limca: DIMETHYL FORMAMIDE
77
4. i) First-in First-out Method (FIFO):
CIMA defines FIFO as ‘a material of pricing the issue of material using the purchase
price of the oldest unit in the stock’. Under this method materials are issued out of
stock in the order in which they were first received into stock. It is assumed that the
first material to come into stores will be the first material to be used.
1100 120
28.08.08 Purchases 500 22 0 0 22 26400
500 22 11000
78
0
120 2640
22.09.08 Issues 0 22 0 300 22 6600
250
200 22 4400 0 22 55000
400 8800
21.11.08 Purchases 0 22 0 900 22 19800
400
0 22 88000
1980 245
19.12.08 Issues 900 22 0 0 22 53900
155 3410
0 22 0
79
0 0 0
110 2420
0 22 0
Under this method most recent purchase will be the first to be issued. The
issues are priced out at the most recent batch received and continue to be charged
until a new batch received is arrived in to stock.
80
0
19.10.0
8 Issues 300 22 6600 700 22 15400
200 22 4400
300 22 6600
21.11.0 400 8800
8 Purchases 0 22 0 700 22 15400
400
0 22 88000
81
155
0 22 34100
105
0 22 23100
In HETERO DRUGS LTD there are certain reasons for slow or non-moving
items. They are as follows:
Order cancel
Products Ban by the Government.
Rejected imported material.
Damage in transit.
Sudden decrease of cost for the products in the market.
Expiry of items.
82
When process changed.
Order cancel: Customers may cancel the orders at any time for different reasons. In
HETERO DRUGS LTD some of the items became non-moving because of
order cancel.
For Example: Premipexale, Di HCL
Products Ban by the Government: Some products are ban by the government due to
different causes. In HETERO DRUGS LTD some products became non-
moving because of products ban by the government. For Example: Valdicoxib
& Gati Floxacan.
Rejected Imported material: In some manufacturing companies once the materials are
imported from other countries they may not be returned if they are damaged. In
HETERO DRUGS LTD some materials are imported from China, US, UK
etc.Once the materials are imported they may not be returned. If they are
damaged or rejected by the Quality control people they may become non-
moving items.
Example: Ikon
83
losses. In HETERO DRUGS LTD some items became non-moving because of
this reason only.
Example: Cetrlin Hydro Chloride.
Expiry of items: Some items may became non-moving because they may reach the
expiry date due to certain reasons. If some items are not used they may expire
and will become non-moving items. In HETERO DRUGS LTD some materials
expired due to process changed. When process changed some items will not be
used.
When process changed: Some items may became non-moving because of process
changed. In HETERO DRUGS LTD some items became non-moving when the
company changes its process due to reduce the cost of production.
For Example: Lisno pril and Fosino pril
All the above are certain reasons for slow or non-moving of items in the stores
]
ECONOMIC ORDER QUANTITY (EOQ):
84
inventory. Stock-out costs are difficult to incorporate into this model. Since they are
based on qualitative and subjective judgment.
The ordering costs are the costs of placing a separate order multiplied by the
number of separate orders placed in the period. The carrying costs can be calculated
based on the assumption that annual cost of carrying a particular stock item on
average, half the stock is on hand all the time in addition to the safety or buffer stock.
The fewer the orders, the lower costs of ordering, but the greater the size of the order
the greater the costs of carrying. The safety or buffer stock has no bearing on the
EOQ, only on the timing of orders. The EOQ is an optimum quantity of materials to
be ordered after consideration. Of the following three categories of costs:
85
• Costs of money tied up in inventory.
• Pilferage and damage costs.
Stock-out Costs: The stock-out costs are associated with running out of stock, which
include the following:
• Lost contribution through the lost sales caused by the stock-out.
• Loss of furniture sales because customers go elsewhere.
• Loss of customer goodwill.
• Cost of production stoppages caused by stock-outs of WIP or raw material.
• Labour frustration.
• Over stoppages.
• Extra costs associated with urgent replenishment purchases of small
quantities.
86
Re-order period 4 to 6 weeks
Solution:
Reorder Quantity
2U x P
S
Where, U= Annual consumption (units) during the year
P= Cost of placing an order
S= Annual carrying cost per unit
2 x 33878 x 300
15
=1164 Kgs
RE-ORDER LEVEL = Maximum usage x Maximum delivery
period
= 420 x 8 = 3360 Kgs
MINIMUM LEVEL = Re-Order level –
(Normal usage x Normal delivery period)
= 3360 - (230 x 7)
= 1750 Kgs
87
= 3652 Kgs
Solution:
Reorder Quantity
2U x P
S
88
2 x 87077 x 600
15
=2640Kgs
6. VED ANALYSIS
VED analysis divides items in to three categories in the descending order of their
critically as follows:
• ‘V’ stands for vital items and their stock analysis requires more attention,
because out-of-stock situation will result in stoppage of production. Thus, ‘V’
items must be stored adequately to ensure smooth operation of the plant.
89
• ‘E’ means essential items. Such items are considered essential for efficient
running but without these items the system would not fail. Care must be taken
to see that they are always in stock.
• ‘D’ stands for desirable item which do not affect the production immediately
but availability of such items will lead to more efficiency and less fatigue.
7. JUST-IN-TIME MANAGEMENT
Japanese firms popularized the Just-in Time (JIT) system in the world. In a JIT
system material or the manufacturing components and parts arrive to the
manufacturing sites or stores just few hours before they are put to use. The delivery
of material is synchronized with the manufacturing cycle and speed. JIT system
eliminates the necessity of carrying large inventories, and thus, saves carrying and
other related costs to the manufacturer.
90
The system requires perfect understanding and coordination between the
manufacturer and suppliers in terms of the timing of delivery and quality of
the material. Poor quality material or components could halt the production.
The JIT inventory system complements the Total Quality Management. The
success of the system depends on how well a company manages its suppliers.
They will have to develop adequate systems and procedures to satisfactory
meet the needs of manufacturers
91
The definition of just in time presented so far can apply to any
material management process, which actively minimizes timescales. The purist
would think that there is more to JIT than this simple concept and there are some
specific concepts for achieving this reduction in timescales, particularly:
• Desire to improve
• Simplification
• Demand-led supply (pull)
• Quality conformance
• Devolution of responsibilit
If these concepts are put into practice, then an operation has a JIT
philosophy supported by improvements in communications and driven by the need
for better service and lower costs, the influence of JIT has been felt in all types of
business and has fuelled change
Advantages of JIT:
Operational benefits:
92
• Simplified administration
• Waste elimination
• Less scrap should there be a problem.
For each of these operational benefits there is a corresponding cost
benefit, which can be offset against any additional costs, which arise. These
additional costs usually occur because methods have not been changed to suit JIT.
For instance: if an item is delivered in a batch once per month, it can be invoiced,
delivery documentation produced and payment made. If through a change to JIT the
item is delivered every day, then it would not be sensible to place a purchase order
for each load, to raise delivery paperwork and to arrange separate payments for each
load. Information is still required for control, but the information system has to be re-
created to meet the new conditions. In the short term this may not be possible and,
so, extra costs can arise. As JIT embodies the process of continuous improvement,
the inefficiency will eventually be eliminated.
Inventory Turn Over Ratio: -
Inventory turn ratio helps management to avoid capital being locked up
unnecessarily. The ratio reveals the efficiency of stock keeping.
Inventory turnover ratio is given by the formula:
This will reveal the number of days for which the stocks are held.
93
Example for Inventory turnover ratio for the year ended 2004-05
Material: 7up (2-METHYL PIPERZINE)
Material consumed during the year = 3317
Cost of Material per Kg = 585
Cost Material consumed = 3317 x 585 =185445
Opening Stock = 918
Cost of Opening Stock = 918 x 585 = 537030
Closing Stock = 63
Cost of Closing Stock = 63 x 585 = 3685
Inventory turnover ratio:
Cost of material consumed
Cost of average stock held during the period
= 185445
286943
= 0.6
94
Example for Inventory turnover ratio for the year ended 2005-06
Material: B - Soda
Material consumed during the year = 301770
Cost of Material per Kg = 30
Cost Material consumed = 301770 x 30 = 9053100
Opening Stock Stock = 12300 x 30 = 369000
Closing Stock = 5700
Cost of Closing Stock = 5700 x 30 = 171000
Inventory turnover ratio:
Cost of material consumed
Cost of average stock held during the period
= 9053100
270000
= 33.53
95
Example for Inventory turnover ratio for the year ended 2006-07
Material: (Kasturi) VANADYL ACETYL ACETONA
Material consumed during the year = 87
Cost of Material per Kg = 29
Cost Material consumed = 87 x 29 = 2523
Opening Stock = 118
Cost of Opening Stock = 118 x 29 = 3422
Closing Stock = 63
Cost of Closing Stock = 63 x 29 = 1827
Inventory turnover ratio:
= Cost of material consumed
Cost of average stock held during the period
= 2523
26245
= 0.09
Cost of average stock :
Cost of Opening Stock + Cost of Closing
2
= 3422 + 1827
2
= 26245
Inventory turnover ratio calculated in days:
= Days during the period
Inventory turnover ratio
= 365
0.09
= 4055 days
96
Example for Inventory turnover ratio for the year ended 2007-08
Material: (Manasa) D (-) MANDALIC ACID
Material consumed during the year = 1215
Cost of Material per Kg = 775
Total Cost of Material consumed = 1215 x 775 = 941625
Opening Stock = 20
Cost of Opening Stock = 20 x 775 = 15500
Closing Stock = 872
Cost of Closing Stock = 872 x 775 = 675800
Inventory turnover ratio:
Cost of material consumed
Cost of average stock held during the period
= 941625
345650
= 2.7
Cost of average stock:
Cost of Opening Stock + Cost of Closing Stock
2
= 15500 + 675800
2
= 345650
Inventory turnover ratio calculated in days:
Days during the period
Inventory turnover ratio
= 365
2.7
= 135 days
97
Example for Inventory turnover ratio for the year ended 2008-09
Material: (Maaza) L-PROLINE
Material consumed during the year = 3050
Cost of Material per Kg = 451
Total Cost of Material consumed = 3050 x 451 = 1375550
Opening Stock = 500
Cost of Opening Stock = 500 x 451 = 225500
Closing Stock = 76
Cost of Closing Stock = 76 x 451 = 34276
Inventory turnover ratio:
Cost of material consumed
Cost of average stock held during the period
= 1375550
129888
= 10.5
98
CHAPTER-VI
FINDINGS&SUGGESTIONS
99
FINDINGS
• During the 2004-05 Inventory turnover ratio (in days) 608 days and 2005-06
inventory turnover ratio 1088days.
• During the 2006-07 inventory turnover ratio(in days) 4055 and 2007-08
inventory turnover ratio 135 days
• The company is not follows the EOQ (economic order quantity) in issuing the
raw material.
• Lead-time for the items was very high. It is high in “A” Class items
• Conversion period was also varying from time to time that is conversion
• Company is follows FIFO (first in first out) to issuing the raw materials to the
100
SUGGESTIONS
• The inventory turnovers ratio during the year 2005-06 are 608 days and 1088
days. The days are increased. It is better to reduce the days because if the days are
increased the cost of maintenance is also increased (holding cost, carrying cost)
• The inventory turnover ratios during the year 2007-08 are 4055 days to 135
days. It is a good signal to the organization why because if the days are decreased the
cost of maintenance is also decreased. If leads to the over ratio cast is also decreased.
• The inventory turnover ratio in the year 2008-09 just 35 days only. It shows
the effective inventory management in Hetero Drugs Ltd.
• JIT system has to be implemented in the hetero Drugs. This system eliminates
the necessity of carrying large inventories, and thus, saves carrying and other
related costs to the manufacturer.
• Finding of items that reached the re-order level and
raise the procurement of Indent is done by the stores clerk. But this can be
done by the system itself by setting the appropriate system software
programmed. It will reduce the workload.
101
all departments concerned.
BIBLIOGRAPHY
102
Referred from the following standard texts and websites:
http://www.Hetero.com
103